Introduction
============

Thyroid cancer (TC) is the most common endocrine malignancy worldwide; the incidence of TC has increased rapidly over the past decade, with an estimated 45,000 new cases diagnosed per year in the United States ([@b1-ol-0-0-11781],[@b2-ol-0-0-11781]). Papillary thyroid carcinoma (PTC) is the most frequent form of TC, accounting for 80--90% of all thyroid malignancies ([@b3-ol-0-0-11781]). PTC variants include conventional, follicular, oncocytic, solid, tall cell, columnar cell, diffuse sclerosing and cribriform forms ([@b4-ol-0-0-11781],[@b5-ol-0-0-11781]). Among these variants, conventional PTC is the main histological variant ([@b6-ol-0-0-11781]). PTC is a well-differentiated papillary carcinoma with a relatively low mortality rate compared with other types of TC, and the 5-year overall survival rate is \>95% ([@b7-ol-0-0-11781]). However, the recurrence or persistence rate of PTC is relatively high ([@b8-ol-0-0-11781],[@b9-ol-0-0-11781]). Potential tumor biomarkers for TC diagnosis and prognosis may serve a significant role in the development of new therapies for TC. Identification of low-risk subsets of patients with PTC may lead to the development of treatments to reduce morbidity. Additionally, identification of patients with PTC that are at a high risk of a poor prognosis may allow for more accurate pre/postoperative assessments and improve the surgical planning based on to the results of the prognostic biomarker tests. Therefore, novel biomarkers or prognostic models are urgently needed to devise new means for the prediction of survival of patients with PTC.

With the advances of genome sequencing technologies in recent years, accumulating evidence have demonstrated that molecular biomarkers, such as protein-coding genes and non-coding RNAs, are informative for cancer detection and classification. mRNAs have exhibited a great potential in both participating in the physiological and pathological processes as well as predicting prognosis of patients with various types of tumor, such as renal cell carcinoma and hepatic carcinoma ([@b10-ol-0-0-11781],[@b11-ol-0-0-11781]). Thus, the dysregulated expression or mutation of mRNAs may be a promising predictor of poor prognosis in PTC. Previous studies have documented that numerous key mRNAs, such as checkpoint kinase 2 (CHEK2) and distal-less homeobox 6 (DLX6), are closely associated with the aggressive pathogenesis of PTC ([@b12-ol-0-0-11781]--[@b14-ol-0-0-11781]). It is likely that multiple mRNAs may allow for the development of a signature model and provide more statistically predictive results of PTCs patients. Thus, a prospective clinical trial using a large cohort is required to investigate specific prognostic classifiers in patients with PTC.

The Cancer Genome Atlas (TCGA) database has publicized various mRNA sequence data, which may provide novel information to improve the understanding of the molecular mechanisms of action in the tumorigenesis and progression of PTC. The current study aimed to apply advanced RNA sequencing analysis to identify differentially expressed mRNAs (DEMs) between PTC samples and normal samples. In additional, the association between prognostic information and expression of these DEMs were evaluated. Functional enrichment analyses were also performed to investigate the mechanisms of action. Furthermore, the application value and reliability of the 5-mRNA signature model to predict PTC prognosis were investigated.

Materials and methods
=====================

### Data collection and pre-processing

mRNA expression information and the corresponding clinical data of 551 samples, including 58 normal and 493 PTC samples, were obtained from TCGA database using the keyword 'thyroid cancer' (<https://tcga-data.nci.nih.gov>) ([@b15-ol-0-0-11781]) prior to July 15th, 2019. As the clinical data and mRNA expression information were downloaded from TCGA database, the current study did not require ethical approval. The mRNAs that were differentially expressed between normal and PTC samples were assessed using R Studio software (RStudio version 1.1.463; <http://www.r-project.org>) ([@b16-ol-0-0-11781]) with the 'limma' package (<http://www.bioconductor.org/packages>). mRNAs that satisfied the criteria \|log~2~ fold change (FC)\|\>2 and P\<0.05 were considered for subsequent analysis ([@b17-ol-0-0-11781]).

### Survival analysis

The Kaplan-Meier analysis and log-rank test were applied to identify the prognostic DEMs. The 'survival' package in the R software (<http://www.bioconductor.org/packages>) was used to construct the survival curves. The survival endpoint was defined as the overall survival time (OS). P\<0.05 was considered to indicate a statistically significant difference. In addition, the median expression value was used as the classification cut-off value for high and low expression.

### Risk stratification and receiver operating characteristic (ROC) curves

To further investigate the crucial DEMs closely associated to OS, univariate Cox models were performed. Subsequently, multivariate COX regression analysis of selected candidate DEMs was performed. DEMs with P\<0.05 were defined as candidate genes for further multivariate Cox regression analysis. Owing to the data processing above, 5 key DEMs were eventually subsumed into the multivariate Cox regression model to calculate their respective coefficients. Then, the score model composed of DEMs\' respective coefficients and expression value was constructed as follows:
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Where k is the number of prognostic RNAs, C~i~ represents the coefficient of the RNA in the multivariate Cox regression analysis, and V~i~ is the expression value of the RNA. The RNAs with C~i~ \>0 were defined as high-risk markers, whereas those with C~i~ \<0 were defined as protective RNAs ([@b18-ol-0-0-11781]). The median risk score was used as the classification cut-off value between high- and low-risk PTC subgroups in 5-mRNA signature model as previously described ([@b19-ol-0-0-11781]). Between the high- and low-risk PTC groups, the difference in OS was compared and analyzed using Kaplan-Meier analysis with the log-rank test. The specificity and sensitivity of the 5-mRNA prognostic signature model in the present study were assessed using an ROC curve and area under the ROC curve (AUC). The 'timeROC' package (<https://cran.r-project.org/web/packages/timeROC/>) was used to conduct all the analyses.

### Prediction of target genes and functional enrichment analysis

Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene ontology (GO) were used to perform functional enrichment analyses of DEMs and to elucidate the mechanisms of action in PTC tumorigenesis using The Database for Annotation, Visualization and Integrated Discovery (<https://david.ncifcrf.gov/>) ([@b20-ol-0-0-11781]).

Results
=======

### DEMs in PTCs

The mRNA expression profiles between PTC and normal samples from TCGA database were downloaded and analyzed. A total of 853 upregulated and 232 downregulated DEMs that met the criteria \|log~2~FC\|\>2 and P\<0.05 were identified in PTC compared with normal samples. The volcano plot and heatmap of the DEMs in PTC are presented in [Fig. 1](#f1-ol-0-0-11781){ref-type="fig"}. The top 10 upregulated and downregulated DEMs were selected for further analysis based on the false discovery rate ([Table I](#tI-ol-0-0-11781){ref-type="table"}).

### Survival analysis

Kaplan-Meier univariate survival analyses were performed in the present study to investigate gene expression profiles on OS. Among the 1,085 DEMs examined in the present study, 361 mRNAs, including adhesion G protein-coupled receptor D1(ADGRD1), ankyrin 2 (ANK2), anoctamin 5 (ANO5), activity regulated cytoskeleton associated protein (ARC), acid sensing ion channel subunit 1 (ASIC1), checkpoint kinase 2 (CHEK2), cytochrome c oxidase subunit 7A1 (COX7A1), casein beta (CSN2), DDB1 and CUL4 associated factor 8 like 1 (DCAF8L1), distal-less homeobox 6 (DLX6), dipeptidyl peptidase like 6 (DPP6), desmocollin 3 (DSC3), elastase, neutrophil expressed (ELANE), erythroferrone (ERFE), coagulation factor X (F10), ficolin 3 (FCN3), FEZ family zinc finger 1 (FEZF1), surfactant protein A1 (SFTPA1), surfactant protein A2 (SFTPA2) and solute carrier family 22 member 31 (SLC22A31), were associated OS in patients with PTC. The top 20 mRNAs based on false discovery rate (FDR) value are presented in [Fig. S1](#SD1-ol-0-0-11781){ref-type="supplementary-material"}.

### Establishment of a five-mRNA signature model

Uni- and multivariate analyses were performed using Cox regression analysis to assess the association between OS and the expression levels of the identified DEMs in patients with PTC ([Table SI](#SD1-ol-0-0-11781){ref-type="supplementary-material"}; [Table II](#tII-ol-0-0-11781){ref-type="table"}). A predictive signature model was established based on five DEMs, namely ADRA1B, RIPPLY3, PCOLCE, TEKT1 and SALL3, that were selected from the multivariate Cox regression analysis. The signature model in the current study was defined as follows: Survival risk score=(−0.771870966 × V~ADRA1B~) + (−0.782948964 × V~RIPPLY3~) + (0.708200312 × V~PCOLCE2~) + (0.241743456 × V~TEKT1~) + (0.378467099 × V~SALL3~), and the V was the expression value ([Table II](#tII-ol-0-0-11781){ref-type="table"}).

### Risk stratification and ROC curve analysis

The risk scores of 493 patients with PTC from TCGA database were calculated using the 5-mRNA prediction model. All patients with PTC were assigned to the low-risk (risk score \>1; n=264) or the high-risk group (risk score ≤1; n=229; [Fig. 2](#f2-ol-0-0-11781){ref-type="fig"}). The prognostic power of the 5-mRNA signature model was evaluated using the AUC value of the ROC curve ([Fig. 3](#f3-ol-0-0-11781){ref-type="fig"}). The 3- and 5-year AUC values in the present study were 0.937 and 0.925, respectively, which demonstrated a high sensitivity and specificity of the 5-mRNA signature model for predicting the risk levels in patients with PTC. This signature model may be used to identify patients with high risk scores who may benefit from more radical, effective and individualized therapy.

### Functional enrichment analysis

The GO analysis results demonstrated that prognostic mRNAs were mainly associated with 'calcium ion binding', 'enzyme inhibitor activity', 'carbohydrate binding', 'transcriptional activator activity', 'RNA polymerase II core promoter proximal region sequence-specific binding' and 'glutathione transferase activity' ([Table III](#tIII-ol-0-0-11781){ref-type="table"}). Using KEGG analysis, five statistically significant pathways were identified, namely 'pertussis', 'ascorbate and aldarate metabolism', 'systemic lupus erythematosus', 'drug metabolism-cytochrome P450' and 'complement and coagulation cascades' ([Table III](#tIII-ol-0-0-11781){ref-type="table"}). These results suggested that the prognostic mRNA are key players in in many cellular and biochemical processes.

Discussion
==========

PTC is a well-differentiated papillary carcinoma with a relatively low mortality rate among types of TC ([@b14-ol-0-0-11781]). However, the persistence and recurrence rates in patients with PTC are high, ≥30% in certain demographics ([@b8-ol-0-0-11781],[@b9-ol-0-0-11781]). Investigation into prognostic biomarkers for predicting the risk for patients with PTC may help develop clear and effective treatment strategies. mRNAs have been considered as prognostic biomarkers for the diagnosis and prognosis for patients with PTC in recent years ([@b21-ol-0-0-11781]). For instance, zinc finger E-box binding homeobox 2 has been reported to be highly expressed in ovarian tumor tissues, which is significantly associated with a poor prognosis ([@b22-ol-0-0-11781]). The expression of Forkhead box Q1 is also negatively associated with patient survival ([@b23-ol-0-0-11781]). It has been reported that the mRNA PFKFB4 is associated with tumorigenesis in TC, with PFKFB4 overexpression promoting migration and invasion of TC cells ([@b24-ol-0-0-11781]). In addition, Huang *et al* ([@b25-ol-0-0-11781]) have demonstrated that the overexpression of JAZF zinc finger 1 mRNA significantly inhibited proliferation, caused cell cycle arrest at the G~0~/G~1~ phase and promoted apoptosis in PTC cells. A previous study has suggested that the upregulation of the cytokine receptor factor-like 1 gene is associated with aggressive clinicopathological features and poor disease-free survival rates in patients with PTC ([@b26-ol-0-0-11781]). Additionally, Vecchio *et al* ([@b27-ol-0-0-11781]) reported that the downregulation of α-L-fucosidase 1 is associated with the increased aggressiveness of TC. A previous study has also identified an association between high expression levels of endo-5′-nucleotidase and the development of metastatic lymph nodes as well as tumor microinvasion in PTC ([@b28-ol-0-0-11781]). However, various mRNA-chip platforms or small number of patients were the major limitations of the aforementioned studies. PTC is a multifactorial disease, in which numerous dysregulated mRNAs participate in the tumorigenesis and progression of the tumor ([@b29-ol-0-0-11781]). Therefore, a signature model including multiple mRNAs may provide a more accurate and detailed prediction system for the diagnosis and prognosis of PTC compared with the use of a single mRNA biomarker.

A total of 853 upregulated and 232 downregulated DEMs in PTC compared with normal thyroid tissues were identified in the present study. Among them, 361 DEMs were associated with OS in patients with PTC. A number of DEMs identified in the present study have been previously investigated in TC. For example, CHEK2 mutations predispose patients to TC, familial breast cancer and double primary cancers of the breast and thyroid ([@b30-ol-0-0-11781]). Variants in the ATM-CHEK2-BRCA1 axis determine genetic predispositions and clinical presentations of PTC ([@b31-ol-0-0-11781]). The ANK2 gene has been demonstrated to exhibit a decrease in expression levels in novel tumors that were identified in pediatric post-Chernobyl tumor cases ([@b32-ol-0-0-11781]). A previous study has demonstrated that ANO5 was downregulated in PTC and follicular thyroid cancer when compared to adjacent non-cancerous tissues ([@b33-ol-0-0-11781]). ANO5 knockdown was also demonstrated to promote thyroid cancer cell invasion and migration *in vitro*; overexpression of ANO5 inhibited these phenotypes ([@b33-ol-0-0-11781]). Tenbaum *et al* ([@b34-ol-0-0-11781]) detected two Alien-specific mRNAs and two Alien-specific proteins *in vivo* and in cell lines; one of the two forms represented the CSN2 subunit of the COP9 signalosome.

Information regarding the regulatory role of ADGRD1, ARC, ASIC1, COX7A1, DCAF8L1, DLX6, DPP6, DSC3, ELANE, ERFE, F10, FCN3, FEZF1, SFTPA1, SFTPA2 and SLC22A31 in PTC is currently limited. However, these DEMs have been reported to be associated with the oncogenesis of other types of cancer in previous studies. For example, the ASIC1 gene is upregulated in pancreatic cancer tissues and expressed on the membrane of pancreatic cancer cells ([@b35-ol-0-0-11781]). Ceder *et al* ([@b36-ol-0-0-11781]) conducted a study that reported that high COX7A1 expression was associated with worse outcome in head and neck squamous cell carcinoma. The DLX6, HOXB7, ELF3, EN1, ETV1, IRX4, BARX1, FOXE1, IRX5 and SALL1 genes are potential oncogenic transcription factors in non-small cell lung cancer cells ([@b37-ol-0-0-11781]). Overexpression of DSC3 reduced cell colony formation and proliferative ability to promote apoptosis and induce G0/G1 cell cycle arrest in colorectal cancer cells ([@b38-ol-0-0-11781]). In addition, the ERFE gene was demonstrated to be associated with OS in colon cancer using univariate Cox regression analysis ([@b39-ol-0-0-11781]). Of note, the FEZF1 gene is an independent predictive factor for cervical cancer recurrence and promotes cervical cancer cell migration and proliferation ([@b40-ol-0-0-11781]). Of note, SLC22A31 mRNA expression levels are associated with OS in right-sided colon cancer, as determined using TCGA data ([@b39-ol-0-0-11781]).

GO and KEGG analyses of 361 prognostic DEMs was performed in the present study to identify the molecular mechanisms of action in PTC. GO and KEGG analyses results suggested that prognostic DEMs are key players in in numerous cellular and biochemical processes. Several signaling pathways and biological processes identified in the present study have been investigated in previous studies on PTC. The stress-activated MAPK signaling pathway is a common pro-oncogenic signaling pathway and tumor suppressor during the process of tumorigenesis in different malignancies including PTC, colorectal cancer, liver cancer and ovarian cancer ([@b41-ol-0-0-11781],[@b42-ol-0-0-11781]). Of note, Li *et al* ([@b43-ol-0-0-11781]) reported that greater heparin binding was achieved by differentially expressed genes in PTC tissues compared with that in normal thyroid tissues. The results of the present study demonstrated that the signaling pathways associated with the complement and coagulation cascades as well as thyroid cancer may also serve important roles in the development of PTC. A previous study revealed that genes involved in a competing endogenous RNA network were significantly enriched during the metabolism of xenobiotics by cytochrome P450 in PTC ([@b44-ol-0-0-11781]). The aforementioned evidence was partially consistent with the results of the present GO and KEGG analyses.

Differential gene expression analysis results in PTC samples demonstrated that the intrathyroidal iodine metabolism machinery, methylation-induced gene silencing of tumor suppressor genes, upregulation of Glut-1 mRNA and pro-angiogenetic proteins such as VEGF were all associated with the impairment of the expression of BRAF genes ([@b45-ol-0-0-11781]). In the present study, it was demonstrated that the 5-mRNAs signature model constructed using TCGA data may be valuable prognostic tool to distinguish patients with PTC into low-risk and high-risk subgroups. Different therapeutic strategies may be selected according to the different risk levels based on the 5-mRNAs signature model, which may help improve the survival of patients with PTC. Patients with PTC in the high-risk group may demonstrate poor clinical outcomes, including aggressive tumor behavior, disease recurrence and disease-specific mortality; therefore, treatment strategies such as prophylactic central neck dissection, radioactive iodine therapy and close long-term follow-up may be applied. Wu *et al* ([@b46-ol-0-0-11781]) identified DEGs related to the progression-free interval (PFI) and applied lasso Cox regression to establish a prognostic gene signature which could predict the PFI of PTC. Similar multi-mRNA prognostic models have also been constructed in other tumor types. A previous study has demonstrated that a 3-mRNA signature (CLEC3B, C6 and CLCN1) model can successfully predict the survival of patients with oral squamous cell carcinoma ([@b47-ol-0-0-11781]). A 24-mRNA signature model was also constructed for early-relapse prediction of patients with hepatocellular carcinoma, which may help facilitate disease management for individual patients ([@b48-ol-0-0-11781]). A metastasis-related 4-mRNA gene signature model has been demonstrated to effectively classify patients with breast cancer into high- and low-risk groups ([@b49-ol-0-0-11781]). In addition, Cui *et al* ([@b38-ol-0-0-11781]) developed a 6-mRNA signature model that may potentially improve the risk stratification of patients with head and neck squamous cell carcinoma ([@b50-ol-0-0-11781]). Liang *et al* ([@b39-ol-0-0-11781]) reported an effective 6-gene prognostic signature model to act as a specific, robust and clinically practical risk stratification model for the survival outcome of patients with cytogenetically normal-acute myeloid leukemia ([@b51-ol-0-0-11781]). Additionally, a prognostic 9-mRNA gene signature model was constructed based on survival data from patients with glioma according to Chinese Glioma Genome Atlas database ([@b52-ol-0-0-11781]).

The present study had certain limitations. First, the mRNA expression data used for the signature model were downloaded from a single database (TCGA) rather than from a number of databases. Additional validation with independent external mRNA expression data is needed to investigate the performance of the 5-mRNAs signature model. Second, the 5-mRNA signature model was constructed using bioinformatics data. Further experimental and clinical studies are required to validate the functions and the predictive value of the 5-mRNA signature model.

In conclusion, in the present study, a 5-mRNA model was constructed to predict the prognosis for patients with PTC. mRNAs with significantly altered expression patterns in PTC may act as prognostic biomarkers. The signature model developed in the present study may improve the prediction of PTC survival and progression.
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###### 

Top 10 upregulated and downregulated differentially expressed mRNAs.

  A, Upregulated mRNAs                                       
  ---------------------------- -------------- -------------- --------------
  ARHGAP36                     8.670156159    1.72×10^−34^   5.05×10^−36^
  SFTPA1                       8.648973385    1.87×10^−21^   1.67×10^−22^
  WIF1                         7.858016530    8.73×10^−13^   1.70×10^−13^
  SERPINB11                    7.516327014    6.02×10^−08^   1.90×10^−08^
  SLC18A3                      7.315944162    8.45×10^−19^   9.47×10^−20^
  SFTPA2                       7.309149505    6.95×10^−22^   6.00×10^−23^
  GABRB2                       7.144823578    1.53×10^−71^   1.04×10^−74^
  TMPRSS6                      7.123312367    2.06×10^−41^   3.30×10^−43^
  SLC22A31                     7.123263970    9.85×10^−57^   3.97×10^−59^
  DPRX                         7.030322665    2.35×10^−07^   7.92×10^−08^
                                                             
  **B, Downregulated mRNAs**                                 
                                                             
  **Gene symbol**              **Log2FC**     **FDR**        **P-values**
                                                             
  OR2V1                        −4.212774737   6.32×10^−43^   8.82×10^−45^
  KCNA1                        −4.091346010   3.91×10^−51^   2.59×10^−53^
  SLC6A15                      −3.985283867   1.61×10^−48^   1.33×10^−50^
  GRIA1                        −3.470505834   9.76×10^−57^   3.87×10^−59^
  VSTM2A                       −3.439852831   1.18×10^−32^   3.94×10^−34^
  UGT2B11                      −3.421202686   1.48×10^−78^   6.70×10^−82^
  RELN                         −3.414498465   2.42×10^−64^   5.35×10^−67^
  MYOC                         −3.390338222   1.13×10^−31^   4.03×10^−33^
  DPT                          −3.282655507   1.28×10^−44^   1.51×10^−46^
  SEC14L3                      −3.276717193   1.48×10^−34^   4.33×10^−36^

FC, fold-change; FDR, false discovery rate.

###### 

Multivariate cox regression analysis between OS and the expression levels of DEMs.

  Gene symbol   Coef           P-value
  ------------- -------------- -----------
  ADRA1B        −0.771870966   2.18×10-3
  RIPPLY3       −0.782948964   9.03×10-4
  TEKT1         0.241743456    9.43×10-2
  PCOLCE2       0.708200312    9.17×10-5
  SALL3         0.378467099    1.67×10-4

Coef, regression coefficient; OS, overall survival; DEMs, differentially expressed mRNAs; ADRA1B, adrenoceptor α-1B; RIPPLY3, ripply transcriptional repressor 3; TEKT1, tektin 1; PCOLCE2, procollagen C-endopeptidase enhancer 2; SALL3, spalt like transcription factor 3.

###### 

Top 10 enriched GO terms, KEGG pathways and target mRNAs.

  A, GO terms                                                                                                                           
  --------------------------------------------------------------------------------------------------------------- ---------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Calcium ion binding                                                                                             0005509    4.705418   PCDHGA12/F10/ADGRE3/MYL3/ENPP2/REG4/CRTAC1/DMP1/MMP19/MMP27/CABP7/PCDH12/PCDH8/MMP28/PADI4/DNASE1L3/PCDH19/DSC3/RGN/CALML6/PCDHA12/SGCA/CSN2/AOC3
  Enzyme inhibitor activity                                                                                       0004857    19.02155   SLN/SCG5/UGT1A1/CSN2
  Carbohydrate binding                                                                                            0030246    26.01117   EMCN/CHIA/OLR1/FCN3/SFTPA2/CHODL/SFTPA1/CLEC4D/CLEC4M
  Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   0001077    27.08023   TCF21/OTX1/DLX5/ONECUT3/SOX2/TP63/NOBOX/PITX3/GRHL1/FOXD1
  Glutathione transferase activity                                                                                0004364    27.42761   GSTA1/CLIC3/ALOX5AP/CLIC5
  RNA polymerase II core promoter proximal region sequence-specific DNA binding                                   0000978    48.17595   FEZF1/MUC1/FEZF2/OTX1/DLX5/NKX3-2/KLF17/NOBOX/PITX3/GRHL1/DDN/FOXD1
  Interleukin-8 binding                                                                                           0019959    52.49444   A2M/CXCR1
  Heparin binding                                                                                                 0008201    58.36638   CCL2/REG4/ELANE/APOH/SERPIND1/GREM2/SOD3
  Structural molecule activity                                                                                    0005198    62.23154   KRT25/DES/KRT74/LAMC3/KRTAP3-2/SYNC/CLDN5/LCE2B/LELP1
  Chloride channel activity                                                                                       0005254    62.51447   CLCA2/GABRR1/CLIC3/CLIC5
                                                                                                                                        
  **B, KEGG pathways**                                                                                                                  
                                                                                                                                        
  **Pathway**                                                                                                     **ID**     **FDR**    **Target mRNAs**
                                                                                                                                        
  Ascorbate and aldarate metabolism                                                                               hsa00053   13.65207   ALDH2/RGN/UGT2B4/UGT1A1
  Systemic lupus erythematosus                                                                                    hsa05322   32.92029   HIST1H2BO/ELANE/HIST1H2BH/C2/HIST1H2AJ/HIST1H3G/HIST1H4J
  Drug metabolism-cytochrome P450                                                                                 hsa00982   33.51738   GSTA1/MAOB/UGT2B4/ADH7/UGT1A1
  Complement and coagulation cascades                                                                             hsa04610   34.81476   A2M/F10/C2/SERPIND1/PLAU
  Metabolism of xenobiotics by cytochrome P450                                                                    hsa00980   41.43999   GSTA1/SULT2A1/UGT2B4/ADH7/UGT1A1
  Chemical carcinogenesis                                                                                         hsa05204   49.49964   GSTA1/SULT2A1/UGT2B4/ADH7/UGT1A1
  Salmonella infection                                                                                            hsa05132   53.48304   PFN2/IL6/WASF1/CXCL2/NOS2
  Morphine addiction                                                                                              hsa05032   63.62918   ADCY4/GABRR1/PDE1B/PDE2A/GABRP
  Alcoholism                                                                                                      hsa05034   70.92004   HIST1H2BO/HIST1H2BH/MAOB/CALML6/HIST1H2AJ/HIST1H3G/HIST1H4J

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.
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